Table 1.
Characteristics of the study population
| Total | HO | NHO | p | |
|---|---|---|---|---|
| n | 517 | 407 | 110 | |
| Age (years) | 67.2 (± 5.9) | 67.7 (± 5.9) | 65.4 (± 5.9) | < 0.001 |
| Sex (women); n (%) | 174 (33.7) | 144 (35.4) | 30 (27.3) | 0.11 |
| BMI (kg/m 2 ) | 33.5 (± 3.3) | 33.5(± 3.2) | 33.4 (± 3.4) | 0.76 |
| Waist (cm) | 110.2 (± 10.3) | 110.4 (± 10.1) | 109.5 (± 10.9) | 0.46 |
| Smoker; n (%) | 67 (13.0) | 54 (13.3) | 13 (11.8) | 0.67 |
| SBP (mmHg) | 149.6 (± 20.4) | 148.5 (± 20.1) | 153.8 (± 20.9) | 0.01 |
| DBP (mmHg) | 86.1 (± 10.6) | 85.6 (± 10.6) | 88.0 (± 10.2) | 0.04 |
| Total cholesterol (mmol/L) | 5.3 (± 1.1) | 5.2 (± 1.1) | 5.6 ± 1.1) | 0.001 |
| LDL-C (mmol/L) | 3.4 (± 1.0) | 3.3 (± 1.0) | 3.7 (± 0.9) | 0.001 |
| HDL-C (mmol/L) | 1.2 (± 0.3) | 1.2 (± 0.3) | 1.2 (± 0.4) | 0.98 |
| Triglycerides (mmol/L) | 1.5 (1.0) | 1.5 (1.0) | 1.6 (1.2) | 0.33 |
| Fasting plasma glucose (mmol/L) | 7.4 (± 2.2) | 7.4 (± 2.1) | 7.2 (2.3) | 0.37 |
| Lipid-lowering drugs; n (%) | 159 (30.8) | 142 (34.9) | 17 (15.5) | < 0.001 |
| Hypertension; n (%) | 467 (90.3) | 371 (91.2) | 96 (87.3) | 0.22 |
| AHT drugs; n (%) | 359 (69.4) | 302 (74.2) | 57 (51.8) | < 0.001 |
| Prevalent diabetes; n (%) | 262 (50.7) | 209 (51.4) | 53 (48.2) | 0.56 |
Values are means (± standard deviation), medians (IQR) or numbers (%). AHT antihypertensive, BMI body mass index, DBP diastolic blood pressure, HDL-C high density lipoprotein concentration, HO hospitalized subjects with obesity, LDL-C low density lipoprotein concentration, NHO non hospitalized subjects with obesity. Bold values denote statistical significance at the p<0.05